Qiagen's QuantiFERON Platform Gains Momentum with New Data and AI Investment

Qiagen recently presented new clinical and health economic data for its QuantiFERON-TB Gold Plus blood test for tuberculosis detection in high-risk and immunocompromised patients. The test has been shown to cut lifetime progression to active TB and lower overall lifetime healthcare costs compared to tuberculin skin testing. This strengthens the medical and economic case for blood-based TB testing, but does not change the near-term focus on expanding test menus and throughput on core platforms such as QIAstat-Dx.